Among GLP-1 pills in development, elecoglipron is an investigational small molecule that activates the GLP-1 receptor. AstraZeneca reported ongoing phase 3 trials in its November 2026 update [2].
What the phase 2 trial found
VISTA randomized 310 adults with obesity or overweight and a related condition [1]. In one 75 mg study group, the efficacy analysis estimated 10.5% weight loss at 26 weeks. The placebo estimate was 0.6%.
At 36 weeks, the same analysis estimated 11.8% weight loss in that group and 0.3% with placebo. The efficacy analysis estimated results if participants stayed on the assigned treatment. VISTA did not compare elecoglipron with other weight-loss drugs.
How it differs from an approved pill
Elecoglipron remains investigational. The FDA approved a different oral small molecule, orforglipron (Foundayo), for weight management in April 2026 [3]. The drugs have separate trials and regulatory records.